Dr Richard Russell
Senior Clinical Research Fellow
- Consultant Respiratory Physician
- Clinical Director Hampshire Integrated Respiratory Service
- Editor in Chief, International Journal of COPD
Past, present and future
Dr Russell graduated in Medicine from Guy's Hospital London. He underwent postgraduate training at Bart's and St George's Hospitals before returning to Guy's to undertake higher specialist training in Respiratory Medicine. He also trained at the Royal Brompton Hospital. His research interests began with a PhD at Imperial College under the supervision of Professor Peter Barnes. This was looking at basic mechanisms of COPD and matrix degradation. He completed his respiratory training and was then a Consultant Physician at Wexham Park Hospital.
Dr Russell is now a Consultant Physician at Lymington New Forest Hospital and is the Clinical Director of the Hampshire Community Integrated Respiratory Service, responsible for asthma and COPD care in community. He is also a PI in Experimental Medicine in the Respiratory Medicine Department at Oxford. His research interests are the basic mechanisms of COPD and asthma and how this leads to new therapeutic possibilities.
Dr Russell is the founding Editor of the International Journal of COPD.
He hopes that the future will bring an end to the curse of tobacco on our world and better treatments for those afflicted with the under-recognised and treated disease that is COPD.
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Baker JR. et al, (2021)
A new piece in the puzzle: the eosinophil and the development of COPD
Petousi N. et al, (2021), European Respiratory Journal, 58, 2101105 - 2101105
Renaming COPD exacerbations: the UK respiratory nursing perspective.
Mwasuku C. et al, (2021), BMC pulmonary medicine, 21
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Yu L-M. et al, (2021), The Lancet, 398, 843 - 855